Quick Answer
ATOSSA THERAPEUTICS, INC. reported Net Income Loss of -$34.77 million for the year ending 2025.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -36.3% in Net Income Loss from 2024 to 2025.
- This data is from ATOSSA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), ATOSSA THERAPEUTICS, INC.'s Net Income Loss has declined by 3,098.9%.
- Historical annual values: Fiscal year 2025: -$34.77 million | Fiscal year 2024: -$25.50 million | Fiscal year 2023: -$30.09 million | Fiscal year 2022: -$26.96 million | Fiscal year 2021: -$20.61 million | Fiscal year 2020: -$17.83 million | Fiscal year 2019: -$17.24 million | Fiscal year 2018: -$11.40 million | Fiscal year 2017: -$8.12 million | Fiscal year 2016: -$6.37 million | Fiscal year 2015: -$15.76 million | Fiscal year 2014: -$14.66 million | Fiscal year 2013: -$10.78 million | Fiscal year 2012: -$5.08 million | Fiscal year 2011: -$3.44 million | Fiscal year 2010: -$1.09 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: